Guardant Health, Inc.
- Open
- 163.79
- Day high
- 168.91
- Day low
- 157.35
- Prev close
- 164.41
- Volume
- 1.7M
- Mkt cap
- $21.9B
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- -98.2
- P/S
- 18.5
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$82.3M over the last 3 months (1 open-market buy, 39 sales)
- 🏛Institutions accumulating (13F)
Guardant Health, Inc. (GH) is a Healthcare company listed on NASDAQ. The stock is up 144% over the past year. Over the trailing 3 months, insiders filed 1 open-market buy and 39 sales (SEC Form 4). Drillr has 2 published research articles covering GH.
Guardant Health, Inc. (GH) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 17 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
GH earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Jul 30, 2026 | $-0.76 | $-0.90 | -18.1% | $335M | +6.6% |
| May 7, 2026 | $-0.47 | $-0.85 | -80.9% | $302M | +8.1% |
| Feb 19, 2026 | $-0.42 | $-0.50 | -19.0% | $281M | +2.0% |
| Oct 29, 2025 | $-0.48 | $-0.39 | +18.7% | $265M | -0.9% |
| Jul 30, 2025 | $-0.52 | $-0.44 | +15.4% | $232M | -1.5% |
| Apr 30, 2025 | $-0.61 | $-0.49 | +19.7% | $203M | -3.8% |
| Feb 20, 2025 | $-0.75 | $-0.62 | +17.3% | $202M | +4.8% |
| May 9, 2024 | $-0.72 | $-0.46 | +36.1% | $168M | +11.8% |
| Feb 22, 2024 | $-0.93 | $-1.58 | -69.9% | $155M | +3.7% |
| Aug 3, 2023 | $-1.25 | $-0.67 | +46.4% | $137M | +6.0% |
| Feb 23, 2023 | $-1.40 | $-1.36 | +2.9% | $127M | +2.0% |
| Nov 3, 2022 | $-1.27 | $-1.58 | -24.4% | $117M | -0.4% |
GH insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 24, 2026 | Talasaz AmirAlidirector, officer: Co-Chief Executive Officer | Sell | 7,589 | $170.29 |
| Aug 24, 2026 | Talasaz AmirAlidirector, officer: Co-Chief Executive Officer | Sell | 20,888 | $169.16 |
| Aug 24, 2026 | Talasaz AmirAlidirector, officer: Co-Chief Executive Officer | Sell | 9,023 | $168.20 |
| Aug 24, 2026 | MIGNONE ROBERTOdirector | Option | 264 | — |
| Aug 18, 2026 | Hidalgo Medina Manueldirector | Option | 232 | — |
| Aug 18, 2026 | Tariq Musadirector | Sell | 116 | $156.45 |
| Aug 18, 2026 | Tariq Musadirector | Option | 250 | — |
| Aug 13, 2026 | Monroe Terilyn J.officer: Chief People Officer | Sell | 3,704 | $163.41 |
| Aug 13, 2026 | Monroe Terilyn J.officer: Chief People Officer | Sell | 9,934 | $164.27 |
| Aug 13, 2026 | Monroe Terilyn J.officer: Chief People Officer | Sell | 13,248 | $166.11 |
| Aug 13, 2026 | Monroe Terilyn J.officer: Chief People Officer | Sell | 400 | $167.92 |
| Aug 13, 2026 | Monroe Terilyn J.officer: Chief People Officer | Option | 32,288 | $20.14 |
| Aug 13, 2026 | Monroe Terilyn J.officer: Chief People Officer | Sell | 19,014 | $165.16 |
| Aug 13, 2026 | Monroe Terilyn J.officer: Chief People Officer | Option | 14,012 | $28.61 |
| Aug 11, 2026 | Freeman Chrisofficer: Chief Commercial Officer | Option | 28,193 | $28.37 |
Source: GH SEC Form 4 filings, latest Aug 24, 2026. For informational purposes only — not investment advice.
See the full GH insider & 13F page →GH research & analysis
[GH] Guardant Health Thesis 2026: Shield CRC Screening Drives Liquid Biopsy Cycle
Guardant Health, Inc. (NASDAQ: GH) FY2025 revenue ~$830-880M (+25-32%) with adj. EPS ~-$3.20 to -$3.55 (continued opex investment + Shield commercial scale-up loss) reflecting continued post-2024 ~$520-555M aggregate Oncology revenue (~63% aggregate revenue mix; selected primary Guardant360 + Reveal MRD/recurrence) + selected continued post-2024 ~$200-225M aggregate Biopharma revenue (~24% aggregate revenue mix) + selected continued post-2024 ~$110-130M aggregate Screening (Shield) revenue (~13% aggregate revenue mix; selected primary post-July 2024 FDA approval) under continued Co-Founders + Co-CEOs Helmy Eltoukhy, PhD + AmirAli Talasaz, PhD since 2012 (~13-year tenure). US specialty cancer + liquid biopsy diagnostics company. Founded 2012 by Helmy Eltoukhy + AmirAli Talasaz in Redwood City California (~13-year heritage; selected pioneer US comprehensive genomic profiling liquid biopsy); selected post-2018 NASDAQ IPO; selected post-2018-2025 ~$2B+ cumulative equity capital; selected post-July 2024 FDA approval (Shield CRC screening); selected post-November 2024 Medicare ADLT $920/test Shield pricing. Headquartered in Redwood City California + Palo Alto California; ~1,800-2,000+ employees globally with ~$830-880M revenue. Three primary business segments: Oncology (~63% ~$520-555M), Biopharma (~24% ~$200-225M), Screening Shield (~13% ~$110-130M). Geographic mix: US ~95%+ + selected various international ~5%. Oncology liquid biopsy cycle (Guardant360 + Reveal): ~$520-555M Oncology revenue; ~225,000-245,000 aggregate annual Oncology tests; ~$2,500-2,800 aggregate Net Sales/test; ~50%+ aggregate US comprehensive genomic profiling liquid biopsy market share. Shield CRC screening launch: ~$110-130M Shield revenue; selected post-July 2024 FDA approval; selected post-November 2024 Medicare ADLT $920/test pricing; ~80-90% aggregate sensitivity stage I-III CRC; ~150M+ aggregate eligible US screening population. Co-Founders + Co-CEOs Helmy Eltoukhy + AmirAli Talasaz since 2012 (~13-year tenure); CFO Mike Bell. Capital position: ~$0.95-1.05B aggregate cash + investments balance; ~$110-150M aggregate quarterly cash burn; selected projected post-2027 cash flow break-even; ~125-130M diluted shares; no dividend (~$0 dividend track post-2018 IPO). FY2026 thesis: Shield CRC screening launch acceleration + Oncology + Reveal MRD growth + selected projected post-2027 cash flow break-even + selected Co-Founder ownership concentration. Risks: Natera + Exact Sciences + Foundation Medicine + Tempus AI + Caris Life Sciences + Cologuard Plus competition, payer access + Medicare reimbursement, sustained cash burn delay break-even.
Non-Colonoscopy Colorectal Cancer Screening Gains Payer Coverage
Labcorp and Guardant Health each cleared ACS guidelines and national payer coverage for non-colonoscopy colorectal screening; Guardant raised guidance to $218-230M.
ABTDGXLH
Guardant Health, Inc. company profile
Overview
Guardant Health, Inc. (NASDAQ:GH) is a precision oncology company founded in 2011 and headquartered in Redwood City, California. The company went public in October 2018 and has established itself as a leader in liquid biopsy technology, which uses blood tests to detect and analyze cancer-related genetic material. Guardant Health operates primarily in the United States with expanding international presence, serving oncologists, patients, and biopharmaceutical companies with innovative blood-based cancer testing solutions.
Business
Guardant Health operates in the precision oncology diagnostics industry, developing and commercializing liquid biopsy tests that analyze circulating tumor DNA (ctDNA) and other biomarkers found in blood samples. Liquid biopsy represents a revolutionary approach to cancer diagnostics, offering a less invasive alternative to traditional tissue biopsies by detecting cancer-related genetic material that tumors shed into the bloodstream. The company's business is organized around three main segments: 1. **Oncology Clinical Testing (~75% of revenue)**: The flagship Guardant360 test serves advanced cancer patients by analyzing 739 genes to identify actionable mutations that can guide targeted therapy selection. The company also offers GuardantOMNI for comprehensive genomic profiling and Guardant Reveal for minimal residual disease (MRD) detection, which monitors whether cancer remains in the body after treatment. Additionally, Guardant provides tissue-based testing through its Guardant360 Tissue product, requiring 40% less tissue than traditional methods. 2. **Biopharma Services (~20% of revenue)**: Through partnerships with over 180 biopharmaceutical companies, Guardant provides companion diagnostic development, clinical trial support, and regulatory services. The company's Smart Liquid Biopsy platform enables drug developers to identify patients most likely to respond to specific treatments and monitor treatment efficacy. 3. **Screening (~5% of revenue)**: The recently launched Shield test represents the first FDA-approved blood test for colorectal cancer screening in average-risk individuals aged 45-84. This test addresses the significant problem of low screening compliance, as traditional colonoscopy screening has participation rates of only about 60% in the eligible population. The company also operates GuardantINFORM, a research platform containing clinical-genomic data from advanced cancer patients, and is developing multi-cancer detection capabilities for early-stage cancer screening.
Revenue model
Guardant Health generates revenue through multiple complementary business models centered around its liquid biopsy technology platform. The primary revenue streams include direct-pay clinical testing services, biopharma partnerships, and emerging screening test sales. For oncology clinical testing, the company charges healthcare providers and payers per test performed. The Guardant360 test commands an average selling price (ASP) of approximately $3,000, significantly higher than the original target of $2,850-2,900 set for 2028. This premium pricing reflects the test's comprehensive 739-gene panel and clinical utility in guiding treatment decisions for advanced cancer patients. The Reveal MRD test and tissue testing products generate additional per-test revenue streams. The biopharma segment operates on a fee-for-service model, providing companion diagnostic development, clinical study support, and testing services to pharmaceutical companies developing cancer therapies. This business benefits from the industry trend toward personalized medicine, where drug approvals increasingly require companion diagnostics to identify appropriate patient populations. The screening business represents a significant growth opportunity, with the Shield test priced at $1,495 for Medicare beneficiaries following its Advanced Diagnostic Laboratory Test (ADLT) designation. The company targets the 120 million Americans eligible for colorectal cancer screening, addressing a market with historically low compliance rates. Revenue growth drivers include expanding test utilization among existing oncology accounts, geographic expansion, new product launches, and increasing reimbursement coverage. The company benefits from secular trends including aging demographics, rising cancer incidence, growing adoption of precision medicine, and increasing preference for less invasive diagnostic procedures. Margin pressures could arise from competitive pricing dynamics, reimbursement rate reductions, regulatory changes affecting coverage policies, or technological disruption from alternative diagnostic approaches. Conversely, margins benefit from economies of scale in laboratory operations, improved test performance requiring less sample processing, and premium pricing for differentiated products with strong clinical evidence.
Competitive moat
Guardant Health's competitive moat stems from several interconnected factors, though the strength of these advantages varies across its business segments. The company's most significant moat lies in its extensive clinical validation and regulatory approvals, particularly the FDA approval of Shield as the first blood-based colorectal cancer screening test. This first-mover advantage provides meaningful protection, as subsequent competitors must demonstrate superior performance to gain market acceptance. The company's Smart Liquid Biopsy platform represents a technological moat built on years of research and development, extensive genomic databases, and proprietary algorithms for detecting and analyzing circulating tumor DNA. The platform's ability to process multiple test types on a single infrastructure creates operational efficiencies and cross-selling opportunities that are difficult for competitors to replicate quickly. Guardant's relationships with over 180 biopharmaceutical partners create a network effect moat, where each new partnership generates data that improves the platform's capabilities, making it more attractive to additional partners. The company's clinical-genomic dataset from hundreds of thousands of patients provides valuable insights that enhance test performance and support new product development. However, the moat faces several challenges. The liquid biopsy field is rapidly evolving with well-funded competitors including Grail (owned by Illumina), Exact Sciences, and Natera. These companies possess similar technological capabilities and are pursuing overlapping market opportunities. Additionally, the core technology relies on next-generation sequencing platforms primarily supplied by Illumina, creating supplier concentration risk. The screening market presents both the greatest opportunity and the most competitive threat. While Guardant currently holds first-mover advantage with Shield, the large market opportunity will likely attract significant competition from established diagnostics companies and well-funded startups. The company's moat in screening depends on maintaining superior test performance, building strong physician relationships, and achieving favorable reimbursement terms before competitors enter the market. Overall, Guardant Health maintains a moderate but not insurmountable competitive moat, with strength varying by business segment and time horizon.
Risks & safety
The company presents moderate financial risk with mixed safety indicators: **Cash Position and Burn Rate:** - Cash and short-term investments: $699 million as of Q1 2025 - Quarterly cash burn: approximately $67 million in free cash flow - Current cash runway: approximately 2.5-3 years at current burn rate - Management targeting cash flow breakeven by 2028 **Debt and Solvency:** - Strong current ratio of 4.1x indicating good short-term liquidity - Quick ratio of 3.8x demonstrates ability to meet immediate obligations - Negative shareholders' equity of -$251 million due to accumulated losses - Debt-to-equity ratio distorted by negative equity but manageable debt levels **Valuation Metrics:** - EV/EBITDA not meaningful due to negative EBITDA - Trading at approximately 7.3x trailing revenue (based on $739M 2024 revenue) - Price-to-book ratio not applicable due to negative book value - High revenue growth (31% in 2024) supporting growth premium **Other Considerations:** - Revenue visibility improving with Medicare coverage for key products - Operating leverage potential as business scales - Regulatory approval risks for pipeline products - Competitive pressure in rapidly evolving market
Recent development
Over the past few years, Guardant Health has executed several strategic initiatives to expand its market presence and product portfolio. The most significant development was achieving FDA approval for the Shield colorectal cancer screening test in 2024, making it the first blood-based screening test approved for average-risk individuals. This milestone was followed by Medicare coverage at $920 per test, with Advanced Diagnostic Laboratory Test (ADLT) status achieved in 2025, increasing reimbursement to $1,495. The company has substantially upgraded its core Guardant360 platform, expanding the gene panel from approximately 70 genes to 739 genes on its Smart Liquid Biopsy platform. This nearly 10-fold increase in testing capability has enabled the company to achieve premium pricing, with average selling prices reaching $3,000, four years ahead of the original 2028 target. In the minimal residual disease (MRD) testing space, Guardant has made significant progress with its Reveal test, achieving Medicare reimbursement for colorectal cancer surveillance and demonstrating strong clinical performance in breast cancer applications. The company has reduced cost of goods sold for Reveal by over 50% and expects the product to achieve gross margin positivity in 2025. International expansion has accelerated, with new laboratory facilities in Spain, partnerships in Japan and China, and a recent collaboration with Abu Dhabi for Shield test distribution. The company has also strengthened its biopharma services business, with the Smart Liquid Biopsy platform now representing over 50% of new contract samples. Looking forward, Guardant is developing multi-cancer detection capabilities, with selection for the National Cancer Institute's Vanguard study demonstrating 60% overall sensitivity for 10 different cancer types. The company is also pursuing lung cancer screening as a second indication for its screening platform and continues to expand the clinical applications of its MRD testing across multiple cancer types.
GH company profile · for informational purposes only — not investment advice.
Track GH with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free